Lexaria to Evaluate Impact of DehydraTECH™ on GLP-1 drugs used in Ozempic®, Wegovy® and Rybelsus®

Lexaria Bioscience Corp. (Nasdaq:LEXX) will expand its established diabetes study program, launching new human and animal studies to evaluate DehydraTECH™-processed glucagon-like peptide-1 (GLP-1) drugs, such as semaglutide, used in Ozempic®, Wegovy® and Rybelsus®.

The drugs will be evaluated for potential improvements in bioavailability, cost-effectiveness, tolerability, weight loss potential, and management of diabetes and other health conditions.

GLP-1 drugs exhibit low oral bioavailability without the use of absorption enhancement technology, such as Lexaria’s DehydraTECH. DehydraTECH-powered GLP-1 drugs could potentially enable drug delivery via oral capsule at lower costs than current injectables, with reduced side effects and enhanced health benefits.

Highlights

  • Lexaria hopes to achieve superior pharmacokinetic (PK) performance using DehydraTECH-powered GLP-1 drugs which could enable drug delivery via oral capsule at lower costs than current injectables, with reduced side effects and enhanced health benefits.
  • The company’s program design has commenced, and initial study work will begin as soon as possible.
  • Lexaria’s preclinical diabetes study evaluating DehydraTECH-CBD in obese diabetic-conditioned animals, achieved statistically significant lowering of blood glucose levels, overall body weight and triglyceride levels, and increasing locomotor activity.
  • The company has also demonstrated in five human clinical studies, that DehydraTECH can greatly improve the PK performance of many orally administered drugs into the bloodstream, such as certain antiviral drugs, estradiol, PDE-5 Inhibitors, cannabinoids and more.

About Lexaria Bioscience

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 36 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article

 

About the Author

Lexaria to Evaluate Impact of DehydraTECH™ on GLP-1 drugs used in Ozempic®, Wegovy® and Rybelsus®

Catie Corcoran

Biotech Editor